CGRP Receptor
Calcitonin gene-related peptide receptor
CGRP receptor is a heterodimer formed by calcitonin-receptor-like receptor (CRLR), a type II (family B) G-protein-coupled receptor, and receptor-activity-modifying protein 1 (RAMP1), a single-membrane-pass protein. RAMP1 is needed for CGRP binding and also cell-surface expression of CLR. CLR is an example of a family B GPCR.
CGRP is a neuropeptide abundant in the trigeminal system and widely expressed in both the peripheral and central nervous systems. CGRP has several functions including vasodilation, the perception of painful stimuli, and inflammation. CGRP exerts its biological action by interacting with its receptors. There are two types of CGRP receptors, CGRP-A and CGRP-B.
All Product Categories
-
CGRP Receptor Related Products (110)
Related Products (110)
-
Antibodies (1)
-
Calcitonin Gene Related Peptide II (rat)
0 ImagesCat. No.: HY-P1913CAS No.: 99889-63-1Synonyms: CGRP II (rat)Calcitonin Gene Related Peptide II rat, a CGRP receptor activator, is a potent and long-lasting vasodilator. Calcitonin Gene Related Peptide II rat can be used in the research of cardiovascular diseases.
-
Fonagepant
0 ImagesCat. No.: HY-P12136CAS No.: 1966181-14-5Synonyms: FE 205030Fonagepant (FE 205030) is a calcitonin gene-related peptide (CGRP) receptor antagonist with an IC50 of 0.2 nM. Fonagepant selectively blocks CGRP receptor activity, inhibits CGRP-induced vasodilation, attenuates capsaicin-induced increase in skin blood flow, and blocks CGRP-induced vasodilation in isolated human mesenteric resistance arteries. Fonagepant can be used in studies related to acute migraine attacks.
-
CGRP antagonist 6
0 ImagesCat. No.: HY-162925CGRP antagonist 6 (Compound 23) is a CGRP receptor antagonist (Ki: 0.84 nM). CGRP antagonist 6 can be used for research of migraine.
-
(Rac)-Vazegepant-13C,d3
0 ImagesCat. No.: HY-134992SSynonyms: (Rac)-Zavegepant-13C,d3; (Rac)-BHV-3500-13C,d3(Rac)-Vazegepant-13C,d3 ((Rac)-Zavegepant-13C,d3; (Rac)-BHV-3500-13C,d3) is the deuterated, 13C-labeled Vazegepant (HY-134992). Vazegepant (Zavegepant; BHV-3500) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki of 23 pM for human CGRP receptor and an EC50 of 880 pM for reversing CGRP-induced vasodilation in human intracranial arteries. Vazegepant can block CGRP-mediated vasodilation in the trigeminal vascular system and inhibit neuronal circuit sensitization. Vazegepant can be used in migraine-related research.
-
Calcitonin (salmon) acetate
0 ImagesSynonyms: Salmon calcitonin acetateCalcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption.The acetate form can affect the absorption and efficacy of hormones.
-
BGM1812
0 ImagesCat. No.: HY-P11587BGM1812 is a dual agonist of amylin (hAMY3R) (EC50 = 0.627 nM) and CGRP Receptor (hCTR) (EC50 = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity.
-
Talogreptide vizaxetan
0 ImagesSynonyms: RM2RM2 is a GRPr antagonist. RM2 selectively binds to GRPr, blocks agonist-induced receptor internalization, and inhibits agonist-triggered intracellular calcium mobilization. RM2 can be used in studies related to prostate cancer.
-
PCC0105005
0 ImagesCat. No.: HY-179684CAS No.: 2921670-99-5PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine.
-
Adrenomedullin (11-50), rat
0 ImagesCat. No.: HY-P1766CAS No.: 163648-32-6Adrenomedullin (11-50), rat is the C-terminal fragment (11-50) of rat adrenomedullin. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors.
-
KBP-042
0 ImagesCat. No.: HY-P11588KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance.
-
BMS-694153
0 ImagesCat. No.: HY-114574CAS No.: 1050381-35-5BMS-694153 is a potent antagonist of the human calcitonin gene-related peptide receptor (CGRP Receptor). BMS-694153 can be used for migraine with rapid and efficient intranasal exposure.
-
Amylin agonist 1
0 ImagesCat. No.: HY-179728Amylin agonist 1 is an agonist of amylin receptor 3 (AMY3R), with an EC50 of 6.17 nM for stimulating cellular cAMP production. Amylin agonist 1 is also an agonist of calcitonin receptor (CTR), with an EC50 of 8.58 nM. Amylin agonist 1 can be used for the research of type 2 diabetes and obesity.
-
KBP-336
0 ImagesCat. No.: HY-P11629KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
-
Drinidene
0 ImagesCat. No.: HY-119864CAS No.: 53394-92-6Drinidene can be used for the research of pain disorders extracted from patent AU2018254530A1.
-
BCTC (Standard)
0 ImagesBCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
-
CTR/AMYR agonist-1 enantiomer
0 ImagesCat. No.: HY-185229ACAS No.: 3108097-24-8CTR/AMYR agonist-1 enantiomer is an enantiomer of CTR/AMYR agonist-1 (HY-185229). CTR/AMYR agonist-1 is a CTR/AMYR agonist with EC50 values of 0.56-6.9 nM. CTR/AMYR agonist-1 can be used for the research of metabolic disease.
-
CGRP antagonist-9
0 ImagesCat. No.: HY-183181CAS No.: 1610413-84-7CGRP antagonist-9 is a CGRP receptor antagonist with an IC50 of 25 nM. It regulates the cAMP signaling pathway and can be used in migraine-related studies.
-
SUN B8155 (Standard)
0 ImagesCat. No.: HY-103302RCAS No.: 345893-91-6SUN B8155 (Standard) is the analytical standard of SUN B8155 (HY-103302). This product is intended for research and analytical applications. SUN B8155, a non-peptide agonist of calcitonin (CT) receptor, selectively mimics the biological actions of calcitonin. Calcitonin, a 32-amino acid peptide hormone secreted mainly from the thyroid gland, plays an important role in maintaining bone homeostasis.
-
Ubrogepant (Standard)
0 ImagesCat. No.: HY-12366RCAS No.: 1374248-77-7Synonyms: MK-1602 (Standard)Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine.
-
Ubrogepant-d5
0 ImagesCat. No.: HY-12366SSynonyms: MK-1602-d5Ubrogepant-d5 (MK-1602-d5) is deuterium labeled Ubrogepant. Ubrogepant (MK-1602) is an orally active and selective antagonist of calcitonin gene-related peptide receptor (CGRP). Ubrogepant has high affinity for CGRP receptors in human and rhesus monkeys, and can effectively block the cAMP response stimulated by α-CGRP. Ubrogepant can be used in the study of acute migraine.
